Neomorph
Bell Zhong is Chief Financial Officer of Neomorph. He is a seasoned finance professional with over 17 years of finance and investment banking experience, advising on capital markets, mergers & acquisitions and other strategic transaction for a wide array of biotechnology and pharmaceutical companies. Throughout his career, he has helped execute over $35bn in equity and equity linked transactions and more than $100bn in M&A transactions for both private and public companies.
Most recently, Bell was Managing Director, healthcare investment banking at Raymond James & Associates, Inc. where he led the banking coverage efforts on a number of innovative biotech companies. Prior to Raymond James, Bell spent over 13 years at J.P. Morgan and was an Executive Director in the healthcare investment banking group, covering the healthcare sector.
Neomorph
1 followers
Neomorph is a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets’.